Animal and human laboratory studies suggest that the pathogenesis of abdominal aortic aneurysms (AAAs) involves inflammation and degradation and remodeling of the extracellular matrix. This study prospectively assessed the association between biomarkers for these mechanisms and the presence of AAA during 24 years of follow-up in the Atherosclerosis Risk in Communities (ARIC) study. The ARIC prospectively identified clinically diagnosed AAAs in 15 792 men and women from baseline in 1987 to 1989 to 2011 using hospital discharge codes and death records. Additional asymptomatic AAAs were detected by an abdominal ultrasound scan in 2011 to 2013. Matrix metalloproteinase (MMP)-3, MMP-9, interleukin 6 (IL-6), N-terminal propeptide of Type III procollagen (PIIINP), and osteopontin were measured in blood samples collected between 1987 and 1992 in participants with AAA (544 clinically diagnosed AAAs and 72 ultrasound-detected AAAs) and a random sample of 723 participants selected from baseline and matched with AAAs by age, race and sex. Higher concentrations of MMP-9 and IL-6 were associated with future risk of clinically diagnosed AAA (hazard ratios [95% confidence intervals]: 1.55 [1.22-1.97] and 1.87 [1.48-2.35], respectively, comparing highest versus lowest tertiles) after multivariable adjustment (P for trend < .001). Matrix metalloproteinase-9 was also associated with ultrasound-detected AAA. In conclusion, blood concentrations of MMP-9 and IL-6 measured in middle age predicted the risk of AAA during 24 years of follow-up.
Introduction
Abdominal aortic aneurysm (AAA) is characterized by progressive and irreversible dilatation of the aortic wall and is associated with high mortality rate when it ruptures.
1,2 The prevalence of AAA increases with age and was reported to be 1% to 2% in women and 4% to 8% in men aged !65 years based on screening programs. 2 The etiology of AAA is incompletely understood. The key pathological feature of AAA is progressive degradation and remodeling of the extracellular matrix (ie, elastin and collagen) in the aortic wall, which is largely mediated by matrix metalloproteinases (MMPs). 3, 4 Animal and human studies document that the destructive remodeling of extracellular matrix in AAA is initiated and exacerbated by a sequence of events at the aortic wall, including activation of chronic inflammation, abnormal response of the innate or adaptive immune systems, and upregulation of MMPs and other proteinases, which are accompanied by impaired compensatory repair of extracellular matrix. [3] [4] [5] [6] [7] Established cardiovascular risk factors, including age, male sex, smoking, and increased low-density lipoprotein (LDL) or total cholesterol, contribute to the etiology of AAA, 2, 8 possibly through these etiopathogenic pathways. 3, 4, 9, 10 Several biomarkers in these pathways have been consistently reported to be elevated in the circulation of patients with AAA. These biomarkers, which are involved in extracellular matrix degradation and remodeling, include MMP-3, MMP-9, N-terminal propeptide of Type III procollagen (PIIINP), 11, 12 and inflammatory biomarkers including interleukin 6 (IL-6) and osteopontin. Association of all of these biomarker with AAA have been reported in cross-sectional, case-control studies, 11, 12 but there is no evidence from population-based prospective studies. Cross-sectional studies are not able to provide information on time sequence between the synthesis of biomarkers and occurrence of disease outcome, which is important for inferring causality.
As part of a research project grant (R01) study funded by the National Institutes of Health, we measured biomarkers of inflammation and extracellular matrix degradation and remodeling (ie, MMP-3, MMP-9, IL-6, osteopontin, and PIIINP) in plasma samples from middle-aged participants of the Atherosclerosis Risk in Communities (ARIC) Study, a large community-based cohort, and prospectively related their levels to the incidence of AAA during 24 years of follow-up.
Materials and Methods

Study Population
Atherosclerosis Risk in Communities is a population-based study investigating the risk factors for atherosclerosis and cardiovascular diseases in a cohort of 15 792 adults aged 45 to 64 years recruited in 1987 to 1989 from Forsyth County, North Carolina; Jackson, Mississippi (African Americans only); the northwest suburbs of Minneapolis, Minnesota; and Washington County, Maryland. 13 The ARIC examined participants at visit 1 in 1987 to 1989 and followed them by annual or semiannual telephone contact and 4 additional reexaminations in 1990 to 1992 (visit 2), 1993 to 1995 (visit 3), 1996 to 1998 (visit 4), and 2011 to 2013 (visit 5). The study was approved by the institutional review board of all participating institutions (leading institution: University of Minnesota, IRB # 8412M01053). All participants provided written informed consent.
Ascertainment of AAAs
The overall design of the study is illustrated in Supplementary  Figure I . As previously reported, 8 we prospectively ascertained incident, clinically diagnosed AAAs by searching hospitalization and death records that were obtained after reports of interim hospitalizations and deaths identified from regular telephone calls with participants (or proxies). The ARIC also con- Figure I) . 8 A radiologist with special vascular imaging expertise centrally trained cardiac ultrasonographers in the technique of abdominal aortic scanning. The abdominal aorta was defined for this study as the aorta from the level immediately below the superior mesenteric artery origin to the aortic bifurcation. After certification, the sonographers obtained transverse images of the abdominal aorta on which they made anterior-posterior and transverse diameter measurements. Imaging was carried out with a Philips iE33 high-resolution duplex scanner and a Philips C5 -1 transducer (Philips Healthcare, Bothell, Washington) following a standardized protocol. 8 A fasting regimen (ie, nothing by mouth) for 6 hours was required before the ultrasound scan was performed. Rare exceptions were given if the participant had to eat before the ultrasound exam could be completed. Vascular imaging physicians overread all images of abdominal aortas that had a ! 2.8 cm maximal infrarenal diameter or probable aortic pathology identified by sonographers, plus a 5% random sample of the remaining cohort. The correlation coefficient for the maximum infrarenal diameter was 0.92 between the physician readers and ultrasonographers. We defined asymptomatic AAA by a maximal infrarenal aortic diameter !3 cm. 1 Of 15 792 ARIC participants who were recruited at baseline, 10 036 participants were still alive through August 2013; 6538 of them had a home or clinic ARIC examination; and 5911 of them had interpretable abdominal aortic ultrasonograms.
Case Cohort Design
A case cohort design was employed to prospectively investigate the role of the biomarkers (ie, MMP-3, MMP-9, IL-6, osteopontin, and PIIINP) measured in blood samples from visit 1 (90% of samples) or visit 2 (10% of samples) in predicting the subsequent risk of AAA through visit 5 (Supplementary Figure I ).
In the entire ARIC cohort, we ascertained 671 AAAs, including 596 incident, clinically diagnosed AAAs identified between visit 1 and the year 2011 during a median of 22.5 years of follow-up, and 75 additional asymptomatic AAAs detected by the ultrasound examination at visit 5 in 2011 to 2013. We excluded 2 clinically diagnosed AAAs which were diagnosed between visits 1 and 2 and for which visit 2 samples were used in the biomarker measurements; we further excluded 50 clinically diagnosed and 3 ultrasound-detected AAAs, which occurred in individuals who were neither white nor African American or for which there was missing information on important covariates or blood samples. The final study included 616 AAAs of which 544 were clinically diagnosed AAAs and 72 were ultrasound-detected AAAs.
The subcohort comparison group was selected randomly from the entire ARIC cohort at baseline without regard to their AAA status during follow-up. Before the subcohort selection, we excluded participants with uncertain AAA status during follow-up (n ¼ 29) or who were missing important covariates (n ¼ 1025). A total of 766 subcohort members were drawn from the eligible ARIC cohort within strata defined by race, gender, and baseline age (>55 vs 55 years) so that the distribution of these variables was comparable between the cases with AAA cases and those in the subcohort group. Of the 766 subcohort members, 43 did not have blood samples from visits 1 and 2, leaving 723 participants in the subcohort group (including 43 with incident, clinically diagnosed AAA and 4 with ultrasound-detected AAAs diagnosed during the followup). Of the 723 subcohort members, 227 had a visit 5 ultrasound examination and thus were eligible to serve as reference for the 72 ultrasound-detected AAAs. Combining the final cases with AAA and subcohort members resulted in a total of 1292 nonoverlapping participants in this study.
Measurement of Traditional Cardiovascular Risk Factors
At each visit, ARIC measured cardiovascular risk factors and conditions including anthropometrics, behavior risk factors, history of physician-diagnosed cardiovascular conditions, and medication use. Details have been described elsewhere. 13 Briefly, ARIC staff measured weight and height with participants in scrub suits and took 3 blood pressure measurements with a random-zero sphygmomanometer. Pack-years of smoking were calculated for current and former smokers as the average number of cigarettes smoked per day multiplied by number of years of smoking divided by 20. At each visit, blood samples were mostly drawn fasting from an antecubital vein. Based on standard protocols, the ARIC central laboratory measured plasma total cholesterol, 14 triglycerides, 15 high-density lipoprotein cholesterol (HDL-C), 16 and calculated LDL cholesterol (LDL-C). 17 
Measurements of Biomarkers
Using EDTA plasma samples that had been collected at visit 1 (90% of samples) or visit 2 (10% of samples) and stored unthawed at À70 C until analysis in 2014 to 2015, ARIC measured plasma concentrations of MMP-3, MMP-9, IL-6, osteopontin, and PIIINP of the cases with AAA and subcohort members. Visit 2 samples were used for participants whose visit 1 samples had been exhausted.
According to manufacturers' protocols, the ARIC laboratory measured MMP-3 and MMP-9 using a fluorokine multianalyte profiling assay (R&D Systems, Inc, Minneapolis, Minnesota) on a Bio-plex 200 System (BioRad, Hercules, California), IL-6 by Quantikine high-sensitivity sandwich enzyme-linked immunosorbent assay (ELISA; R&D Systems, Inc,), osteopontin by Quantikine sandwich ELISA (R&D Systems, Inc,), and PIIINP by sandwich ELISA (Cloud-Clone Corp, Houston, Texas cat# SEA573Hu). The intra-and interassay coefficients of variations percentage for the ARIC samples are presented in Table 1 . In addition, we analyzed repeatability of 58 to 59 blind duplicate pairs of ARIC visit 1 samples split at the time of blood draw and stored until the laboratory assay of this study. The intraclass correlation coefficients for the duplicate pairs are reported in Table 1 as well.
Data Analysis
Since some of the cardiovascular risk factors that were associated with the survival of the patients who had an ultrasound are also risk factors for AAA, analyzing the clinically diagnosed AAAs and ultrasound-detected AAAs together might cause bias in the estimates of associations between risk factors and AAA. Therefore, we analyzed the associations between AAA and each of the biomarkers separately for clinically diagnosed and ultrasound-detected AAAs and adjusted for the potential selection bias caused by differential attrition in the analysis of the ultrasound-detected AAA (see details in the analysis of ultrasound-detected AAAs below). The entire subcohort group served as the comparison for clinically diagnosed AAAs, and the subcohort members who attended the ultrasound 
, and osteopontin (n ¼ 30). We also conducted a sensitivity analysis to winsorize these extreme values rather than excluding them.
Association analyses of the biomarkers with clinically diagnosed AAAs. We analyzed the time-to-event data using the Cox proportional hazard models and weighted each stratum of the subcohort group by the reciprocals of the sampling rates. To account for some participants being in both the case and the subcohort groups, we applied the weighting method and robust variance estimation proposed for case-cohort studies by Barlow et al. 18, 19 Participants were categorized into tertiles of each biomarker based on the distribution in the subcohort group. We calculated hazard ratios (HRs) and 95% confidence intervals (CIs) of AAA in relation to the tertiles and tested trends by modeling tertile as an ordinal variable. The analysis was adjusted for age, sex, and combination of race-field center in a basic model (model 1) and further adjusted for the following traditional risk factors in model 2 based on our prior knowledge of risk factors for clinically diagnosed AAA: height, pack-years of smoking, hypertension, diabetes, total cholesterol, and HDL-C. 8 All of the covariates were measured at the same visit as the sample collection for the biomarkers. As cigarette smoking is a very strong risk factor for AAA, we also stratified the analyses in model 2 by smoking status (ever and never) and tested for multiplicative interactions of biomarkers by smoking.
Association analysis of the biomarkers with ultrasound-detected AAAs. We employed generalized linear model (GLM) to estimate the odds ratios (OR) and 95% CI for the association of ultrasound-detected AAA with each biomarker in tertiles. The Schouten et al sandwich estimator of the covariance matrix for log (OR) was used to adjust for the overlap of some cases with AAA among the subcohort members in the variance estimate for the log (OR). 20 Since a number of participants were lost to follow-up or died prior to the visit 5 ultrasound examination, we used inverse probability of attrition weighting as described previously 21 to adjust for the potential selection bias caused by differential attrition due to loss to follow-up. We first calculated the ultrasound attendance probability as the product of the probability of being alive at visit 5 and the probability of having an abdominal ultrasound conditional on being alive, given relevant covariates measured at baseline and during follow-up. 8, 22 A composite weight was then derived as the product of the ultrasound attendance probability and the sampling fractions of cases and subcohort members. The regression coefficients and 95% CIs were obtained from GLMs using a logit link function. The covariance matrix was estimated using the sandwich estimator, and each participant was inverse weighted by the composite weight as described earlier. Similar to the analysis of clinically diagnosed AAAs, we adjusted for covariates in models 1 and 2 based on our prior knowledge on risk factors for ultrasound-detected AAA in ARIC, 8 and we tested for trend across tertiles of the biomarkers.
Secondary analyses of the biomarker-AAA associations. To evaluate whether significant biomarker associations with AAA might have been confounded by mix of samples from different visits and whether the associations were independent of other cardiovascular risk factors (ie, body mass index [BMI], waist circumference, peripheral arterial disease [PAD] , coronary heart disease [CHD] , and use of antihypertensive or lipidlowering medications), and the previously reported biomarkers in ARIC, 22 we further adjusted for sample visit, these cardiovascular risk factors, and biomarkers in the following potential pathways for AAA 22 : (1) Since there was a varying degree of missing data for these biomarkers (n of missingness ¼ 6 to 345), we focused on effect sizes, instead of P values, in assessing the influence of the adjustment on the biomarker-AAA associations.
To infer a possible role of the biomarkers in early versus late stage development of AAA, we reran the analysis of clinically diagnosed AAAs after excluding AAAs that were diagnosed within 10 years of the baseline.
Risk prediction analysis for clinically diagnosed AAAs. We calculated Harrel's C-index in Stata 15.1 to assess the predictive ability for clinically diagnosed AAA in 3 risk factor models using the approach proposed by Sanderson et al for case-cohort studies. 23 Prentice weights 24 were used to incorporate the contribution of nonsubcohort cases. A robust jackknife estimator for standard error was implemented. The 3 risk factor models are: model 1 traditional risk factors: age, sex, race-field center, height, smoking pack-years, hypertension, diabetes, total cholesterol, and HDL-C; model 2 variables in model 1 plus the significant biomarkers identified in this study (MMP-9, IL-6, and osteopontin); and model 3 variables in model 2 plus the biomarkers previously reported in ARIC and measured at the same visit as the 3 significant biomarkers of this study: WBC, fibrinogen, antithrombin III, and lipoprotein (a).
22,25
Results
As shown in Table 2 , the participants who developed clinically diagnosed AAA and those with ultrasound-detected AAA at visit 5 had poorer cardiovascular risk factor profiles at baseline compared to their subcohort comparison groups. Furthermore, participants who developed clinically diagnosed AAA tended to have poorer risk factor levels than participants with ultrasound-detected AAA. The median and mean (SD) times to event for clinically diagnosed AAAs were 15.8 and 14.5 (5.6) years, respectively.
The associations between the biomarkers and incident, clinically diagnosed AAA are shown in Table 3 . After adjustment for age, sex, and race-field center in model 1, baseline MMP-9, IL-6, PIIINP, and osteopontin were significantly and positively associated with clinically diagnosed AAA, with respective HRs (95% CI) of 1.82 (1.46-2.27), 2.31 (1.84-2.90), 1.27 (1.02-1.60), and 1.36 (1.08-1.70) for the highest versus lowest tertiles. Further adjustment for other AAA risk factors in Model 2 moderately attenuated the associations, with those for MMP-9, IL-6, and osteopontin remaining statistically significant with a dose-response relationship. The smoking-stratified analyses included 475 and 69 AAAs in ever smokers and never smokers, respectively. As shown in Supplementary Figure II , the associations of MMP-9, IL-6, and osteopontin with AAA were positive and significant for ever smokers, with the strength of the associations being similar to that in the whole sample. The associations for these biomarkers were weaker and not significant in never smokers (P for interaction with smoking status < .0001 for MMP-9, IL-6, and osteopontin).
Of the biomarkers that were significantly associated with clinically diagnosed AAA, MMP-9 was significantly and strongly associated with visit 5 ultrasound-detected AAA, independent of age, sex, race, height, total cholesterol, triglycerides, and pack-years of smoking (Table 4 ). The associations of PIIINP and osteopontin with ultrasound-detected AAAs were similar to those with clinically diagnosed AAA but were not statistically significant (Table 4 ) likely due to limited statistical power. Interleukin-6 was clearly not associated with ultrasound-detected AAA.
Secondary analyses of the biomarker-AAA associations.
(1) Winsorization of outliers (>6SD from the mean) rather than excluding them did not result in appreciable changes in the associations between the biomarkers and the clinically diagnosed AAA (Supplementary Table I ). The winsorization transformation was not applicable to the ultrasounddetected AAA analysis because the outlier samples did not participate in the abdominal ultrasound examination. (2) Exclusion of 116 clinically diagnosed AAAs which were diagnosed within 10 years of baseline did not materially change the associations for MMP-9 or IL-6, while the association for osteopontin was strongly attenuated (Supplementary Table II ). (3) Additional adjustment for sample visit, BMI, waist circumference, PAD, CHD, or use of antihypertensive medication did not appreciably change the associations of most of the biomarkers with either clinically diagnosed AAA or ultrasound-detected AAA (data not shown). The only exception was that adjustment for PAD or CHD modestly attenuated the association between osteopontin and clinically diagnosed AAA so that it was no longer significant: HR associated with the highest tertile of osteopontin (P for trend) ¼ 1.22 (0.10) and 1.21 (0.11) after adjusting for PAD and CHD, respectively (Supplementary Table III) . Adjustment for the use of lipid-lowering Table V) .
Risk prediction analysis for clinically-diagnosed AAAs. Table 5 presents C-index for the prediction of clinically diagnosed AAA in 3 risk factor sets. The 3 biomarkers identified in our study did not significantly increase the predictive ability beyond the traditional risk factors nor did the previously reported biomarkers beyond the 3-biomarker set sequentially. However, combining the previously reported biomarkers with the 3-biomarker set resulted in statistically significant increase in the predictive ability beyond the traditional risk factors (C-index increment ¼ 0.011, P ¼ .04; Table 5 ). 
Discussion
To the best of our knowledge, this is the first populationbased, prospective study of long follow-up to investigate the association of these biomarkers of inflammation and extracellular matrix degradation and remodeling with the risk of AAA. Based on a median of 22.5 years of follow-up, we found that higher MMP-9 and IL-6 measured at baseline were associated with greater risk of clinically diagnosed AAA, independent of the influence of established risk factors for AAA. MMP-9 was also significantly and positively associated with the risk of asymptomatic AAA detected by the ARIC ultrasound examination at the end of the follow-up. The associations of MMP-9 and IL-6 were also present for clinically diagnosed AAAs detected in the more distant future, that is, after 10 years of follow-up. As the pathogenesis of AAA may have started years before an aortic diameter meets the diagnostic criteria or a clinical event occurs, the robust findings in this sensitivity analysis indicate that these 2 biomarkers are not likely the by-product during the complex process of AAA development, thus proving support for the inference of a causal relationship between these biomarkers and AAA.
Matrix metalloproteinase-9, also named gelatinase B, is produced by many types of cells including leukocytes. 26, 27 It is capable of degrading intact elastin fibers, 4 and it is the most abundant MMP produced by AAA tissues in vitro. 28, 29 The messenger RNA expression of MMP-9 in AAA tissues correlates with aneurysm diameter. 30 Matrix metalloproteinase-9 knockout mice are resistant to experimentally-induced AAA, 31 and wild-type bone marrow transplantation removed the resistance. 4 Of all MMPs that have been investigated crosssectionally in the circulation of patients with AAA and normal controls, MMP-9 showed the most consistent association with AAA. 11, 12 In a recent genome-wide association study of AAA, Jones et al 32 identified direct interaction of MMP-9 gene with several genome-wide significant genes at gene expression level, including ERG, IL6R, and LDLR. These and our findings together support the hypothesis that elevated MMP-9 plays an important role in the etiology of AAA.
In our study, adjustment for WBC moderately attenuated the associations of MMP-9 with both clinically diagnosed and ultrasound-detected AAAs, but the association with ultrasound-detected AAAs remained strong and significant. It is debatable whether WBC should be adjusted for as a confounder because MMP-9 is not only an effector but also a regulator of leukocyte biology. Leukocytes may be one of the sources for circulating MMP-9. 33 Circulating levels of MMP-9 correlated with WBC, with a stronger correlation in current smokers (r 2 ¼ .21) than never smokers (r 2 ¼.07). 33 In humans, chemokines such as IL-8 stimulate the release of MMP-9 by neutrophils, which in turn further stimulates the activation and chemotaxis of neutrophils via its effect on IL-8. 34 In transgenic mouse models, MMP-9 was found to play a role in the process of hematopoiesis, that is, recruitment of blood cells from the bone marrow. 35 In the context of the mutual regulation between leukocytes and MMP-9, adjustment for WBC in the analysis of MMP-9 with AAA may be "overadjustment."
Interleukin-6 is a pleiotropic cytokine that participates in the regulation of homeostasis via pro-and anti-inflammatory properties. 36 Interleukin-6 exerts a protective role in the body's acute response to many infections but seems harmful when it is chronically elevated, as elevated plasma IL-6 is associated with increased risk of chronic conditions such as CHD 37 and rheumatoid arthritis. 36, 38 Interleukin-6 has been identified as an important pro-inflammatory cytokine in the pathogenesis of AAA. It promotes MMP expression by directly stimulating MMP production by inflammatory cells. 4, 39 Interleukin-6 levels were significantly higher in AAA biopsies than controls. 40 Experimentally induced AAA was suppressed in mice with targeted deletion of IL-6 or in wild-type mice treated with anti-IL6 antibody. 3 In addition to previously reported cross sectional associations with AAA, 11, 12, 41 circulating IL-6 was positively correlated with aortic diameters in individuals without AAA, 42 suggesting that IL-6 may be involved in the early stage of AAA formation. Moreover, a Mendelian randomization study linked an IL6 R genetic variant with AAA risk. 41 In our study, the prospective association of IL-6 with AAA remained significant after we controlled for the other inflammatory biomarkers, supporting an independent contribution of the IL-6 pathway to the etiology of AAA.
Interleukin 6 was not associated with ultrasound-detected AAA in our study. Compared to the entire subcohort group, participants who survived and attended the visit 5 ultrasound examination had a healthier risk factor profile and lower degree of inflammation as reflected by lower levels of CRP, fibrinogen, and IL-6 ( Table 2 ). It is possible that the IL-6 pathway may not have been activated sufficiently to contribute to the risk of AAA in the relatively healthy survival cohort. Alternatively, and quite likely, the absence of association between IL-6 and ultrasound-detected AAA may be due to poor statistical power resulting from a limited number of cases.
Osteopontin is an acidic glycoprotein and exerts pleiotropic functions in tissue repair, remodeling, inflammation, and immune response. [43] [44] [45] It has been demonstrated to upregulate pro-MMP-9 activation 46 and was increased in human AAA tissue. 47 Osteopontin-deficient mice had reduced AAA formation induced by angiotensin II infusion and exhibited decreased activity of MMPs including MMP-9. 48 In our study, the association of osteopontin with AAA was modestly attenuated after additional adjustment for PAD or CHD and largely attenuated after excluding clinically diagnosed AAAs who were diagnosed within the first 10 years of baseline. This suggests that osteopontin may be involved in a later stage of AAA development, and its association with AAA is not independent of the influence of PAD and CHD.
Given the biological relationship between IL-6, MMP-9, and osteopontin, we further included the 3 biomarkers simultaneously in model 2 for clinically diagnosed AAA analysis to investigate the independence of the biomarkers. After simultaneous adjustment for each other, the association of MMP-9 and IL-6 with AAA remained significant (MMP-9: HR ¼ 1.15 and 1.32 for the second and third tertiles versus the first tertile, P for trend ¼ .03; IL-6: HR ¼ 1.38 and 1.78, P < .001) while that for osteopontin was no longer significant (HR ¼ 0.99 and 1.14, P ¼ .30). This observation further corroborates our postulation that osteopontin may be a downstream reactor to MMP-9 and IL-6, and its elevation probably occurs at a later stage of AAA development.
Smoking is the strongest risk factor for AAA, increasing AAA lifetime risk by 5-fold compared to never smokers. 8 The association of MMP-9, IL-6, and osteopontin were mainly present in ever smokers but not in never smokers in our study. While the role of these biomarkers in never smokers needs further investigation in larger samples, our findings in ever smokers is in line with current understanding of the pathophysiology of AAA. In the etiopathologic pathways for AAA, cigarette extracts activate many downstream events, including the expression and activity of MMPs, systemic and local inflammation and apoptosis of smooth muscle cells, 49, 50 all of which contribute to the pathogenesis of AAA. While smoking prevention and cessation are the most effective strategies in AAA prevention, the effect of smoking on AAA lasts for at least 10 years after smoking cessation. 2, 8 Therefore, our study provides insights into the relative etiologic importance of these biomarkers for AAA in people with a smoking history, which may improve risk stratification and prevention of AAA as well as aid in the identification of drug targets for AAA treatment in this high-risk population. Future research is warranted to investigate longitudinal changes in these biomarkers in relation to smoking cessation to better understand the role of these biomarkers in AAA development due to smoking.
The strengths and limitations of this study warrant discussion. This study reports data from a large, population-based prospective cohort that has been followed for >20 years. The longitudinal design provides supportive evidence for causality. We included both clinically diagnosed AAAs ascertained from event follow-up and additional asymptomatic AAAs detected at ultrasound screening. The biomarkers were selected based on accumulating evidence from animal and human studies.
However, we also recognize the following limitations. First, due to the lack of an ultrasound screening at baseline, we might have still included some prevalent AAAs in the cohort at baseline even after exclusion of patients with AAA repair prior to the baseline evaluation. However, the prevalence of AAA should have been low at the baseline age of 45 to 64 years, and the associations for MMP-9 and IL-6 remained consistent and significant after exclusion of clinically diagnosed AAAs ascertained within 10 years of baseline. Second, the biomarkers in this study were measured in blood samples after long-term freezer storage. If there is any change in the biomarkers due to sample degradation, the change should be nondifferential with regard to AAA status. Consequently, the influence would have been minimal if the relative ranking of individuals in the population based on the biomarkers was not changed or would most likely have diluted the strength of associations if the relative ranking of the biomarkers was changed. We noticed that the reliability coefficients of the blind duplicate pairs were poorer (<0.5) for MMP-3 and MMP-9 than that for the other assays. These blind pairs were drawn in separate vacutainers in 1 draw but were processed and analyzed separately and thus reflect processing, storage, and laboratory variability. One possibility is that the MMP analytes were more sensitive to longterm storage than the others. The influence of the measurement errors for these analytes should be nondifferential with regard to case status and thus would have unlikely resulted in spurious positive associations between the biomarkers and AAA. Third, in our study, we used an ELISA-type method to measure circulating levels of total MMPs (both pro-MMPs [inactive form] and cleaved MMPs [active form]). Since we did not specifically measure plasma MMP activities, we cannot comment on possible associations of MMP activities with future risk of developing AAA in this ARIC cohort. Fourth, residual confounding by other risk factors (eg, smoking) could have occurred, although we have adjusted for those risk factors in Model 2. In the analysis adjusting for the previously reported biomarkers, there might still have been residual influences of some of these biomarkers because they were measured in samples obtained at later visits (ie, CRP, D-dimer, cTnT, and NT-proBNP). Fifth, other biomarkers that were reported to be different in patients with AAA versus controls (eg, tissue inhibitor of matrix metallo-proteinase 1 [TIMP-1] and a1-antitrypsin) 12 are not available in ARIC and warrant future investigation in prospective studies. Notably, TIMP-1 is a physiological inhibitor of MMP-9, and a1-antitrypsin is a protease inhibitor that protects tissues from the action of various proteases including elastase. 12 Therefore, these 2 proteins might play a role in the pathogenesis of AAA. Finally, we used case-cohort design with slightly more controls than a 1:1 ratio. The estimates of biomarker-AAA associations and risk prediction analysis would be more accurate and associated with better statistical power if more controls were included, ideally by inclusion of the whole ARIC cohort. Future studies in different populations with similar or larger sample size are needed to confirm the findings from our study.
In summary, in this community-based prospective study with a long follow-up, higher concentrations MMP-9 and IL-6 were associated with future risk of AAA, independent of the established AAA risk factors. Our findings corroborate the evidence from animal and human laboratory studies and highlight the role of inflammation and extracellular matrix degradation in the development of AAA. Future studies with longitudinal measurements of both the biomarkers and ultrasound examination are needed to assess whether the longitudinal trend of these biomarkers predicts AAA progression and rupture.
